HARMONi-2 study shows OS benefit for ivonescimab monotherapy vs pembrolizumab
Summit Therapeutics said Akeso announced positive overall survival results from the Phase III HARMONi-2 randomized, double-blind study comparing ivonescimab and pembrolizumab monotherapy in PD-L1-positive advanced NSCLC.
Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive overall survival (OS) results from the randomized, double-blind Phase III HARMONi-2 study evaluating ivonescimab monotherapy against pembrolizumab monotherapy in patients with locally advanced or meta…